Andres Gomez, Associate Professor of Hematology at UANL, Monterrey, Mexico, shared on X:
“More is not necessarily better.
DA-EPOCH-R + venetoclax in double-hit lymphoma: a cautionary tale from Alliance A051701. More intensity ≠ better outcomes.”
Title: Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
Authors: Jeremy S Abramson, Susan Geyer, Sharmila Giri, Levi Pederson, Ann Hudson, Eric D Hsi, Neha Mehta-Shah, Patrick M Reagan, Richard L Deming, Richard F Little, Steven Gore, Shira N Dinner, Anusha Vallurupalli, Daniel J Landsburg, Brad Kahl, Jonathan W Friedberg, Nancy L Bartlett, John P Leonard.
Read the full article.
You might be interested:
